Oncolytics Biotech (ONCY) and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at SITC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. N2EW34
9. INTC
10. IMNN

Go back to Oncolytics Biotech (ONCY) and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at SITC

Oncolytics Biotech (ONCY) Reports Q3 Loss of $0.16

November 11, 2020 4:52 PM EST

Oncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.16), versus ($0.16) reported last year.

Financial Highlights

As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million during the third quarter through the issuing of common stock through our ATM facility.Operating expense for the third quarter of 2020 was $2.5 million, compared to $1.8 million in the third quarter of 2019.R&D expense for the third quarter of 2020 was $3.9 million, compared to $1.7 million in the third quarter of 2019.Net cash used in operating activities for the third... More